Vamshi Krishna Tippavajhala


Hypertension or elevated blood pressure is a common chronic disease. It is associated with severe symptoms like aneurysms, chronic kidney disease, amnesia, improper speech, blindness, peripheral artery disease, brain stroke, heart attack etc. Pathophysiology for hypertension involves the role of autonomous nervous system, cardiac output and renin-angiotensin aldosterone system. This review article mainly deals with the application of nanotechnology and nanoparticulate drug delivery systems in the formulation of various antihypertensive drugs for the treatment of hypertension. Applications of various nanoparticulate drug delivery systems like solid lipid nanoparticles, polymeric nanoparticles, nanosuspensions and self-nanoemulsifying drug delivery systems for antihypertensive drugs have been reviewed and discussed in this article which indicate that the bioavailability of various poorly soluble and permeable antihypertensive drugs can be improved using these nano carriers.

Full Text:



Solak Y, Afsar B, Vaziri ND, Aslan G, Yalcin CE, Covic A, et al. Hypertension as an autoimmune and inflammatory disease. Hypertens Res. 2016;39(8):567-73.

Hypertension (High Blood Pressure): Symptoms [Internet]. National Library of Medicine - PubMed Health. 2017 [cited 13 March, 2017]. Available from: https://www.ncbi.nlm.nih.gov/pubmedhealth/PMHT0024201/

Beevers G, Lip GYH, O'Brien E. The pathophysiology of hypertension. BMJ : British Medical Journal. 2001;322(7291):912-6.

Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: analysis of worldwide data. The Lancet. 2005;365(9455):217-23.

Anchala R, Kannuri NK, Pant H, Khan H, Franco OH, Di Angelantonio E, et al. Hypertension in India: a systematic review and meta-analysis of prevalence, awareness, and control of hypertension. Journal of Hypertension. 2014;32(6):1170-7.

Ali MA, Rizvi S, Syed BA. Trends in the market for antihypertensive drugs. Nat Rev Drug Discov. 2017;advance online publication.

Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, Jr., et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. Jama. 2003;289(19):2560-72.

Hansson L, Zanchetti A, Carruthers SG, Dahlöf B, Elmfeldt D, Julius S, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. The Lancet.351(9118):1755-62.

James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). Jama. 2014;311(5):507-20.

Sharma M, Sharma R, Jain DK. Nanotechnology Based Approaches for Enhancing Oral Bioavailability of Poorly Water Soluble Antihypertensive Drugs. Scientifica. 2016;2016:8525679.

Leroueil-Le Verger M, Fluckiger L, Kim YI, Hoffman M, Maincent P. Preparation and characterization of nanoparticles containing an antihypertensive agent. European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik eV. 1998;46(2):137-43.

Li P, Dai Y-N, Zhang J-P, Wang A-Q, Wei Q. Chitosan-Alginate Nanoparticles as a Novel Drug Delivery System for Nifedipine. International Journal of Biomedical Science : IJBS. 2008;4(3):221-8.

Ekambaram P, Abdul HSA. Formulation and Evaluation of Solid Lipid Nanoparticles of Ramipril. Journal of Young Pharmacists : JYP. 2011;3(3):216-20.

Jana U, Mohanty AK, Pal SL, Manna PK, Mohanta GP. Felodipine loaded PLGA nanoparticles: preparation, physicochemical characterization and in vivo toxicity study. Nano Convergence. 2014;1(1):31.

Chonkar AD, Rao JV, Managuli RS, Mutalik S, Dengale S, Jain P, et al. Development of fast dissolving oral films containing lercanidipine HCl nanoparticles in semicrystalline polymeric matrix for enhanced dissolution and ex vivo permeation. European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik eV. 2016;103:179-91.

Nekkanti V, Wang Z, Betageri GV. Pharmacokinetic Evaluation of Improved Oral Bioavailability of Valsartan: Proliposomes Versus Self-Nanoemulsifying Drug Delivery System. AAPS PharmSciTech. 2016;17(4):851-62.

Li XJ, Yuan H, Zhou ZL, Hu W. The study on valsartan solid lipid nanoparticles. Chinese Journal of Pharmaceutical Biotechnology. 2015;22(1):29-32.


  • There are currently no refbacks.